CH568392A5 - - Google Patents

Info

Publication number
CH568392A5
CH568392A5 CH1297272A CH1297272A CH568392A5 CH 568392 A5 CH568392 A5 CH 568392A5 CH 1297272 A CH1297272 A CH 1297272A CH 1297272 A CH1297272 A CH 1297272A CH 568392 A5 CH568392 A5 CH 568392A5
Authority
CH
Switzerland
Application number
CH1297272A
Original Assignee
Bayern Freistaat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712145477 external-priority patent/DE2145477C3/en
Application filed by Bayern Freistaat filed Critical Bayern Freistaat
Publication of CH568392A5 publication Critical patent/CH568392A5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CH1297272A 1971-09-11 1972-09-08 CH568392A5 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19712145477 DE2145477C3 (en) 1971-09-11 Vaccine for intracutaneous smallpox vaccination

Publications (1)

Publication Number Publication Date
CH568392A5 true CH568392A5 (en) 1975-10-31

Family

ID=5819271

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1297272A CH568392A5 (en) 1971-09-11 1972-09-08

Country Status (5)

Country Link
AT (1) AT320149B (en)
BE (1) BE787901A (en)
CH (1) CH568392A5 (en)
DK (1) DK137392C (en)
ES (1) ES406590A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157528A2 (en) * 1984-03-28 1985-10-09 Chiba Prefectural Government Attenuated smallpox vaccine strain
EP0324350B1 (en) * 1988-01-12 1993-11-10 F. Hoffmann-La Roche Ag Recombinant vaccinia virus MVA
US6440422B1 (en) 1995-07-04 2002-08-27 Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh Recombinant MVA virus, and the use thereof
EP2264178A1 (en) 2002-08-07 2010-12-22 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of Avipoxviruses
WO2011042180A1 (en) 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
EP2319860A2 (en) 2004-08-27 2011-05-11 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
EP2359851A2 (en) 2003-03-28 2011-08-24 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
DE102013004595A1 (en) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV vaccines
WO2017120577A1 (en) 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3988651A1 (en) 2007-05-14 2022-04-27 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
US11666651B2 (en) 2019-11-14 2023-06-06 Aelix Therapeutics, S.L. Prime/boost immunization regimen against HIV-1 utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (en) * 1977-04-01 1978-10-05 Mayr Anton PREPARATION FOR TREATING HERPES ZOSTER AND OTHER HERPES INFECTIONS AND METHOD FOR THE PRODUCTION THEREOF

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157528A3 (en) * 1984-03-28 1986-12-30 Chiba Serum Institute, (Of Chiba Prefectural Government) Attenuated smallpox vaccine strain
EP0157528A2 (en) * 1984-03-28 1985-10-09 Chiba Prefectural Government Attenuated smallpox vaccine strain
EP0324350B1 (en) * 1988-01-12 1993-11-10 F. Hoffmann-La Roche Ag Recombinant vaccinia virus MVA
US8153138B2 (en) 1995-07-04 2012-04-10 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Recombinant MVA virus
US6440422B1 (en) 1995-07-04 2002-08-27 Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh Recombinant MVA virus, and the use thereof
US7198934B2 (en) 1995-07-04 2007-04-03 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Recombinant MVA virus, and the use thereof
US8197825B2 (en) 1995-07-04 2012-06-12 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Recombinant MVA virus and the use thereof
EP2264178A1 (en) 2002-08-07 2010-12-22 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of Avipoxviruses
EP2363143A2 (en) 2003-03-28 2011-09-07 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
EP2371380A1 (en) 2003-03-28 2011-10-05 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
EP2359851A2 (en) 2003-03-28 2011-08-24 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
EP2319860A2 (en) 2004-08-27 2011-05-11 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
EP3988651A1 (en) 2007-05-14 2022-04-27 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
WO2011042180A1 (en) 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2013110818A2 (en) 2012-01-27 2013-08-01 Laboratorios Del Dr. Esteve, S.A. Immunogens for hiv vaccination
US11919926B2 (en) 2012-01-27 2024-03-05 Esteve Pharmaceuticals, S.A. Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
US9988425B2 (en) 2012-01-27 2018-06-05 Laboratories Del Dr. Esteve S.A. Immunogens for HIV vaccination
US10815278B2 (en) 2012-01-27 2020-10-27 Laboratorios Del Dr. Esteve S.A. Immunogens for HIV vaccination
EP4163290A1 (en) 2012-01-27 2023-04-12 Esteve Pharmaceuticals, S.A. Immunogens for hiv vaccination
US11325946B2 (en) 2012-01-27 2022-05-10 Laboratorios Del Dr. Esteve S.A. Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes
DE102013004595A1 (en) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV vaccines
WO2017120577A1 (en) 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
US11666651B2 (en) 2019-11-14 2023-06-06 Aelix Therapeutics, S.L. Prime/boost immunization regimen against HIV-1 utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN

Also Published As

Publication number Publication date
AT320149B (en) 1975-01-27
BE787901A (en) 1972-12-18
DE2145477B2 (en) 1976-04-01
DK137392B (en) 1978-02-27
DK137392C (en) 1978-09-18
ES406590A1 (en) 1975-09-16
DE2145477A1 (en) 1973-03-15

Similar Documents

Publication Publication Date Title
ATA136472A (en)
AR196074A1 (en)
AU2658571A (en)
AU2691671A (en)
AU2485671A (en)
AU2742671A (en)
AU2564071A (en)
AU2684071A (en)
AU2455871A (en)
AU1109576A (en)
AU2706571A (en)
AU2669471A (en)
AU2724971A (en)
AU2654071A (en)
AU2588771A (en)
AU2577671A (en)
AU2726271A (en)
AU2503871A (en)
AU2885171A (en)
AU2836771A (en)
AU2837671A (en)
AU2880771A (en)
AU2473671A (en)
AU2456871A (en)
AU2875571A (en)

Legal Events

Date Code Title Description
PUE Assignment

Owner name: PROF. DR. MED. HELMUT A. STICKL

PL Patent ceased
PL Patent ceased